a public good project by the
Synthesis
Company
of California

© 2026

William J. Greenlee | doi.page

0 works0 citations0 h-index

William J. Greenlee

Med Discovery (Switzerland)(CH)

Publications by Year

Research Areas

Receptor Mechanisms and Signaling, Renin-Angiotensin System Studies, Computational Drug Discovery Methods, Chemical Synthesis and Analysis, Cholinesterase and Neurodegenerative Diseases

Most-Cited Works

→ Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy(1996)310 cited
→ SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infectionin vitroandin vivo(2001)300 cited
→ Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity(2008)267 cited
→ 5-Chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase(1993)266 cited
→ Renin inhibitors(1990)248 cited
→ Identification of peptide binding residues in the extracellular domains of the AT1 receptor.(1994)170 cited

→ Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease(2016)

161 cited

→ Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor(2012)151 cited

→ Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines(2006)136 cited

→ Discovery of Potent Orally Active Thrombin Receptor (Protease Activated Receptor 1) Antagonists as Novel Antithrombotic Agents(2005)123 cited